Vivacelle Bio, Inc.
Chicago, United States (US) · Health and Medical
Do your work at Vivacelle Bio, Inc.?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Last verified
May 2026
Vivacelle Bio, Inc. is a Health and Medical company based in Chicago, United States (US), founded in 2013, with 2-10 employees. Vivacelle Bio, Inc.'s profile is verified on Enterprise League.
Overview
Vivacelle Bio is a late-stage biopharma company based in Kansas City, Missouri, developing life-saving treatments for shock and trauma. Leveraging our pioneering and patented phospholipid nanoparticle technology, we address the urgent global crisis of sepsis and acute hemorrhage.
Millions of lives are lost each year due to sepsis, a leading cause of death worldwide, often stemming from relative or absolute hypovolemia. Our lead product, VBI-S, utilizes a unique mechanism to redistribute nitric oxide, elevating blood pressure in patients who are refractory to standard fluid therapy.
This innovative approach represents a new paradigm in critical care, offering a potential lifeline for patients facing devastating outcomes. We’ve secured backing from venture capital, the US Department of Defense, and the National Institutes of Health, and are currently enrolling patients in a Phase III clinical trial. VBI-S aims to transform treatment outcomes and save countless lives.
We are committed to advancing this technology and bringing a much-needed solution to patients and healthcare providers worldwide.
Millions of lives are lost each year due to sepsis, a leading cause of death worldwide, often stemming from relative or absolute hypovolemia. Our lead product, VBI-S, utilizes a unique mechanism to redistribute nitric oxide, elevating blood pressure in patients who are refractory to standard fluid therapy.
This innovative approach represents a new paradigm in critical care, offering a potential lifeline for patients facing devastating outcomes. We’ve secured backing from venture capital, the US Department of Defense, and the National Institutes of Health, and are currently enrolling patients in a Phase III clinical trial. VBI-S aims to transform treatment outcomes and save countless lives.
We are committed to advancing this technology and bringing a much-needed solution to patients and healthcare providers worldwide.
Contact Details
info@vivacellebio.com
Chicago, United States (US), EnterpriseWorks Chicago
+1
Founded
2013
Company Type
Private Limited Company
Employees
2-10
Categories
Keywords
#bionanotechnology
#micelles
#treatment for hypovolemia
#biotechnology
Companies teams usually look at after Vivacelle Bio, Inc.
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.